Market Snapshot

BSE Sensex: 80951.99 -0.79%
BSE 500: 35542.53 -0.56%
BSE 200: 11171.96 -0.65%
BSE 100: 25795.88 -0.71%
BSE MidCap: 44638.43 -0.33%
BSE SmallCap: 51289.32 0.17%
BSE BANKEX: 62348.33 -0.27%
BSE IT: 36615.34 -1.09%
Nifty 50: 24609.7 -0.82%
Nifty 500: 22595 -0.60%
Nifty 200: 13698.55 -0.70%
Nifty 100: 25221.9 -0.74%
Nifty Midcap 100: 56324.85 -0.52%
Nifty Small 100: 17503.1 -0.26%
Nifty IT: 37050.1 -1.31%
Nifty PSU Bank: 6667.95 -0.58%

News:

Mehai Tech Q4 PAT soars to Rs ...
Subros Q4 PAT climbs 52% YoY o...
Interglobe Aviation Q4 PAT ris...
BSE drops as SEBI mulls Tuesda...
Deepak Fertilisers records ove...

Shilpa Medicare Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

22 May 2025 | 04:14 PM

735.60

33.15 (4.72%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

49.28%

Return (1Y)

Beaten Nifty 50 by 39.14%
More Volatile

3.16%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.17%
Consistent Performer

8/12

Months

beaten Nifty 50
AxisDirect View

No View

52 Week High-Low

960

418

News & Announcements

Shilpa Medicare to conduct board meeting
3 days ago

Shilpa Medicare to conduct board meeting

19 - May - 2025 12:00 | 3 days ago

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 26 May 2025.
Powered by Capital Market - Live News
Shilpa Medicare gains after arm receives EIR from USFDA for unit-1 facility
7 days ago

Shilpa Medicare gains after arm receives EIR from USFDA for unit-1 facility

15 - May - 2025 12:00 | 7 days ago

In an exchange filing, the company stated that the USFDA has classified the inspection outcome as voluntary action indicated (VAI). The inspection was conducted at the Unit-1 facility from 3 March to 7 March 2025.
The official announcement was made on 14 May 2025, after market hours.
Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India.
The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year.
Powered by Capital Market - Live News
Shilpa Medicare receives USFDA approval for Varenicline Tablets
43 days ago

Shilpa Medicare receives USFDA approval for Varenicline Tablets

09 - Apr - 2025 12:00 | 43 days ago

Shilpa Medicare has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg.

The total US market for this product is around 203 M USD.

Shilpa's product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism).

Varenicline Tablets are indicated for smoking cessation; it helps people to quit smoking.
Powered by Capital Market - Live News
Shilpa Medicare receives USFDA approval for Varenicline tablets
43 days ago

Shilpa Medicare receives USFDA approval for Varenicline tablets

09 - Apr - 2025 12:00 | 43 days ago

Varenicline helps people quit smoking by blocking the effect of nicotine on the brain. Nicotine is a substance found in cigarettes and other tobacco products that makes smoking feel good. Varenicline blocks this good feeling and can help prevent cravings to smoke cigarettes.
The total US market for varenicline products is around $203 million.
Shilpa?s product has been approved as a generic version of the innovator, Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism).
Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India.
The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year.
Shares of Shilpa Medicare tumbled 3.64% to Rs 620.10 on the BSE.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Shilpa Medicare Ltd has increased by 10.78% since past 3 Months
MF shareholding in Shilpa Medicare Ltd has decreased by -17.26% since past 3 Months
FII shareholding in Shilpa Medicare Ltd has increased by 92.95% since past 1 Year
MF shareholding in Shilpa Medicare Ltd has increased by 154.8% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

General Notifications

My Notifications

Research Notifications

Shilpa Medicare Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

735.60 33.15 (4.72%)

News & Announcements

Price vs Volume

Stock Trivia

Shilpa Medicare Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

735.60

33.15 (4.72%)